Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up

BJU International

Volumn 111, Issue 7, 2013, Pages 1046-1053

  Zhang, Ben Y ^a   Thompson, R Houston ^a   Lohse, Christine M ^a   Dronca, Roxana S ^a   Cheville, John C ^a   Kwon, Eugene D ^a   Leibovich, Bradley C ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

carbonic anhydrase IX (CAIX); prognosis; renal cell carcinoma (RCC)

Indexed keywords

CARBONATE DEHYDRATASE IX;

AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY SURGERY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR NECROSIS;

AGED; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NECROSIS; NEPHRECTOMY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUESTIONNAIRES; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877702039     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12075     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96
2. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590
3. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134
4. Shvarts O, Seligson D, Lam J, et al. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol 2005; 173: 725-728
5. Klatte T, Seligson DB, Riggs SB, et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007; 13: 7388-7393
6. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006; 7: 556-564
7. Brunelli M, Eccher A, Gobbo S, et al. Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod Pathol 2008; 21: 1-6
8. Thompson RH, Kwon ED,. Significance of B7-H1 overexpression in kidney cancer. Clin Genitourin Cancer 2006; 5: 206-211
9. Parker AS, Leibovich BC, Lohse CM, et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009; 115: 2092-2103
10. Swinson DE, Jones JL, Richardson D, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003; 21: 473-482
11. Leibovich BC, Sheinin Y, Lohse CM, et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007; 25: 4757-4764
12. Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ,. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997; 57: 2827-2831
13. Genega EM, Ghebremichael M, Najarian R, et al. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol 2010; 134: 873-879
14. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 802-811
15. Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T,. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 2007; 100: 556-560
16. Patard JJ, Fergelot P, Karakiewicz PI, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 2008; 123: 395-400
17. Kim HL, Seligson D, Liu X, et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004; 10: 5464-5471
18. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11: 3714-3721
19. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E,. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 2010; 58: 75-83
20. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 98: 2566-2575
21. Kroeger N, Seligson DB, Klatte T, et al. Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma. Eur Urol 2012; 61: 888-895
22. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007; 8: 304-310
23. Pryma DA, O'Donoghue JA, Humm JL, et al. Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250. J Nucl Med 2011; 52: 535-540
24. Davis ID, Wiseman GA, Lee FT, et al. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun 2007; 7: 13
25. Bleumer I, Knuth A, Oosterwijk E, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004; 90: 985-990
26. Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 2006; 175: 57-62
27. Divgi CR, O'Donoghue JA, Welt S, et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 2004; 45: 1412-1421
28. Uemura H, Fujimoto K, Tanaka M, et al. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 2006; 12: 1768-1775